Table 1.
Baseline characteristics of the patients
| Characteristic* | Conventional cohort (n = 562) | ICU cohort (n = 269) |
|---|---|---|
| Age, y | 61.1 ± 15.1 | 61.2 ± 11.5 |
| Sex, male, n (%) | 349 (62.1) | 187 (69.5) |
| Body mass index, kg/m2 | 29.0 ± 5.8 | 30.9 ± 5.6 |
| Previous medical history, % | ||
| Smokers | 35.1 | 38.8 |
| Alcohol | 19.3 | 12.8 |
| Arterial hypertension | 42.5 | 49.8 |
| Ischemic cardiopathy | 7.3 | 7.5 |
| Pulmonary embolism | 3.9 | 3.4 |
| Deep vein thrombosis | 4.8 | 3.4 |
| Diabetes | 23 | 33.5 |
| COPD | 6.2 | 3.3 |
| Asthma | 8.50 | 5.6 |
| Obstructive sleep apnea | 10 | 8.6 |
| Cancer | 10.7 | 7.8 |
| Immunosuppression | 3.7 | 4.1 |
| Daily treatments, % | ||
| Inhibitors of angiotensin converting enzyme | 15.2 | 15.6 |
| Aldosterone antagonists | 15.7 | 16.4 |
| Beta-blockers | 18.4 | 19.3 |
| Corticosteroids | 8.4 | 7.1 |
| Immunosuppressors | 2.7 | 3 |
| Antiplatelets agents | 14.4 | 11.9 |
| Anticoagulants | 11.4 | 8.1 |
| COVID-19 symptoms, % | ||
| Fever | 69.4 | 65 |
| Asthenia | 73.3 | 59 |
| Cough | 72.2 | 62.9 |
| Dyspnea | 70.3 | 81.6 |
| Chest pain | 20.8 | 11 |
| Myalgia | 35.5 | 25.5 |
| Diarrhoea | 36.1 | 27.9 |
| Vomiting | 22.4 | 14.7 |
| Headache | 30.6 | 17.2 |
| Cutaneous rash | 2.8 | 2.7 |
| Ageusia | 24.6 | 13.7 |
| Anosmia | 20.7 | 13.7 |
| pH | 7.50 (7.40–7.50) | 7.50 (7.40–7.50) |
| PaO2, mmHg | 71.1 (62.3–84) | 72.9 (61.6–88.2) |
| PaCO2, mmHg | 34.5 (31.2–37.5) | 34.0 (30.0–39.1) |
| PaO2/FiO2 | 286 (188–331) | 102.0 (80.5–155.5) |
| Supplemental Oxygen < 5L/min, % | 91.3 | |
| Supplemental Oxygen > 5L/min, % | 5.1 | |
| High flow oxygenation, % | 3.6 | 60.6 |
| Invasive mechanical ventilation, % | 0 | 30.5 |
| Vasopressors, % | 0 | 10 |
| Extra renal therapy, % | 0 | 0.4 |
| Antibiotics, % | 20.3 | 37.5 |
| sTREM-1, pg/mL | 147 (76–249) | 224 (144–320) |
| Interleukin-6, pg/mL | 16 (7–36) | 45 (15–98) |
| Interleukin-1b, pg/mL | 0.2 (0.2–0.2) | |
| Interleukin-8, pg/mL | 20 (14–31) | |
| Interleukin-10, pg/mL | 13 (8–22) | |
| Interferon-γ, pg/mL | 4 (1–10) | |
| Chemokine ligand-2, pg/mL | 363 (282–691) | |
| Angiopoietin-2, pg/mL | 1298 (896–2010) | |
*Data are presented as means (standard deviation), percentages, or medians (interquartile range)